Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biogen Inc. (BIIB) has announced an update on its Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL).’ The study aims to evaluate the effects of felzartamab on proteinuria in patients with Immunoglobulin A nephropathy (IgAN), a kidney condition that causes protein in the urine due to kidney damage. The primary goal is to assess how felzartamab affects protein levels in urine over 36 weeks, alongside evaluating kidney function and safety.
The study involves administering intravenous (IV) doses of felzartamab, an experimental drug, compared to a placebo. The treatment period lasts 24 weeks, followed by an 80-week follow-up. Participants are randomly assigned to receive either the drug or placebo, with neither participants nor researchers aware of the assignments, ensuring unbiased results.
The study is designed as a randomized, parallel, quadruple-masked trial with a primary treatment purpose. It started on May 8, 2025, with the last update on July 9, 2025. The primary completion and estimated study completion dates are yet to be announced.
This update could influence Biogen’s stock performance positively, as successful results may enhance investor confidence and position the company favorably against competitors in the nephropathy treatment market. The ongoing recruitment and study progress are crucial for stakeholders to monitor.
The study is currently recruiting, with further details available on the ClinicalTrials portal.